- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Bradley Monk Discusses PARP Inhibitor Reimbursement
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.
Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, head of the US Oncology Gynecologic Research Committee, and current co-director for the Gynecologic Oncology Group Research Consortium, discusses the reimbursement landscape of PARP inhibitors in ovarian cancer.
Transcript
How has the reimbursement landscape for PARP inhibitors evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
Reimbursement for PARP inhibition has been universal in the United States and even in Europe. These new frontline PARP inhibitor indications of PRIMA [trial] and the PAOLA-1 [trial]—PRIMA niraparib alone, PAOLA-1 bevacizumab and olaparib—have now been approved in Europe. Europe is trafficking through reimbursement, but in the United States are universally paid for. The only caveat is that in the bevacizumab-olaparib combination there is a companion diagnostic, so generally reimbursement is only for those patients that have the molecular HRD [homologous recombination deficiency] signature.
Even though PARP inhibitors have been paid for through insurances, which is universally true, there are still copays, and copays are the real financial burden. The companies try to support through copay assistance programs, they have foundations, but there still is a substantial financial burden to these expensive oral medications. Someday there'll be generic, and we already have multiple biosimilars for bevacizumab, and we're seeing the prices come down.
So in the end, it's all about value. And the value of PARP inhibitors, obviously, is the most in BRCA-mutated patients—either germline or somatic, it's about the same—but also a lot of value in the HRD, BRCA-like gene subset. The value in the patients that are what we call homologous recombination proficient is not as much, but they're still approved, and certainly there is a value issue with bevacizumab. And when you add bevacizumab and olaparib together, then obviously 2 medications are more expensive than 1.
Alzheimer Disease and Related Dementias Cause Surging Economic Burden for Minoritized Communities
June 5th 2025African American and Latino older adults with Alzheimer disease and related dementias and their families are likely to face disproportionately high burdens, primarily associated with unpaid caregiving, suggesting the need for policies that may reduce economic burdens for all US residents.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
